Announcement of the company's cash capital increase and base date
2019.Jun.10
Board of directors of the company waived subscription rights exceeding half of the total subscribable shares. Shares to be subscribed by designated persons
2019.May.06
Letter received from National Medical Products Administration (NMPA) of China regarding Adagloxad Simolenin (OBI-822) Phase III clinical study to be resubmitted after supplementation
2019.Apr.22
Supplementary announcement for the company to issue ordinary shares through rights offering
2019.Apr.19
Supplementary announcement for 2019 Annual General Meeting
2019.Apr.18
Announcement for the company to issue ordinary shares through rights offering and bank designated for collection and deposition
2019.Apr.13
Clearance of Adagloxad Simolenin (OBI-822) for a Phase III clinical study by Ministry of Health of the Russian Federation
2019.Apr.09
Announcement for the company to issue ordinary shares through rights offering
2019.Mar.27
Announcement of capital change registration for the treasury share retirement
2019.Mar.08
The board of directors have resolved not to distribute dividends for 2018